Geron Corp (GERN) Posts Disappointing Q4 Results

Geron Corporation (GERN) reported fourth quarter EPS of ($0.06) after close Tuesday, compared to the consensus estimate of $0.17. Revenues decreased 20.9% from last year to $178K. Analysts expected revenues of $35.35 million. The stock is now down $0.01 to $2.95 on 2.17 million shares.

Net loss for 2014 was $35.7 million, or $0.23 per share, compared to $38.4 million, or $0.30 per share, for 2013.

On valuation measures, Geron Corp. shares, which currently have an average 3-month trading volume of 2.8 million shares, trade with a P/E to growth ratio of (5.25). Currently ticker boasts 2 ‘Buy’ endorsements, compared to 2 ’Holds’ and no ‘Sell’.

Profitability-wise, GERN has a t-12 operating margin of (3,012%). The $465.34 million market cap company reported $170.06 million in cash vs. $0 in debt in its most recent quarter.

GERN currently prints a one year loss of about 33% and a year-to-date loss of around 7%.

The chart below shows where the equity has traded over the last 52 weeks.

Geron Corp. is a clinical stage biopharmaceutical firm focused on the development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.